177 related articles for article (PubMed ID: 10828874)
1. Infusion of lymphocytes obtained from a donor immunised with the paraprotein idiotype as a treatment in a relapsed myeloma.
Cabrera R; Díaz-Espada F; Barrios Y; Briz M; Forés R; Barbolla L; Sanjuán I; Regidor C; Peñalver FJ; Fernández MN
Bone Marrow Transplant; 2000 May; 25(10):1105-8. PubMed ID: 10828874
[TBL] [Abstract][Full Text] [Related]
2. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
Peggs KS; Mackinnon S; Williams CD; D'Sa S; Thuraisundaram D; Kyriakou C; Morris EC; Hale G; Waldmann H; Linch DC; Goldstone AH; Yong K
Biol Blood Marrow Transplant; 2003 Apr; 9(4):257-65. PubMed ID: 12720218
[TBL] [Abstract][Full Text] [Related]
3. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation.
Mandigers CM; Verdonck LF; Meijerink JP; Dekker AW; Schattenberg AV; Raemaekers JM
Bone Marrow Transplant; 2003 Dec; 32(12):1159-63. PubMed ID: 14647270
[TBL] [Abstract][Full Text] [Related]
4. Discrepancy between serological complete remission and concomitant new bone lytic lesions after infusion of escalating low doses of donor lymphocytes in multiple myeloma: a case report.
Rondelli D; Bandini G; Cavo M; Re F; Motta M; Senese B; Leopardi G; Stanzani M; Tura S
Bone Marrow Transplant; 1999 Sep; 24(6):685-7. PubMed ID: 10490737
[TBL] [Abstract][Full Text] [Related]
5. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome.
Lokhorst HM; Schattenberg A; Cornelissen JJ; van Oers MH; Fibbe W; Russell I; Donk NW; Verdonck LF
J Clin Oncol; 2000 Aug; 18(16):3031-7. PubMed ID: 10944138
[TBL] [Abstract][Full Text] [Related]
6. Long-term remission of paraprotein-induced immunotactoid glomerulopathy after high-dose therapy and autologous blood stem cell transplantation.
Witzens-Harig M; Waldherr R; Beimler J; Zeier M; Hansmann J; Ho AD; Goldschmidt H; Moehler T
Ann Hematol; 2007 Dec; 86(12):927-30. PubMed ID: 17605010
[No Abstract] [Full Text] [Related]
7. Transfer of idiotypic protein primed allogeneic marrow grafts elicits potent graft-versus-myeloma effects in mice.
Zeis M; Steinmann J; Petrela E; Hartung G; Schmitz N; Uharek L
Bone Marrow Transplant; 2001 Feb; 27(3):279-85. PubMed ID: 11277175
[TBL] [Abstract][Full Text] [Related]
8. Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion.
Orsini E; Bellucci R; Alyea EP; Schlossman R; Canning C; McLaughlin S; Ghia P; Anderson KC; Ritz J
Cancer Res; 2003 May; 63(10):2561-8. PubMed ID: 12750280
[TBL] [Abstract][Full Text] [Related]
9. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma.
Boccadoro M; Palumbo A; Bringhen S; Merletti F; Ciccone G; Richiardi L; Rus C; Bertola A; Giaccone L; Omedè P; Musto P
Haematologica; 2002 Aug; 87(8):846-50. PubMed ID: 12161361
[TBL] [Abstract][Full Text] [Related]
10. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma.
Neelapu SS; Munshi NC; Jagannath S; Watson TM; Pennington R; Reynolds C; Barlogie B; Kwak LW
Bone Marrow Transplant; 2005 Aug; 36(4):315-23. PubMed ID: 15968284
[TBL] [Abstract][Full Text] [Related]
11. Donor leukocyte infusions for multiple myeloma.
Salama M; Nevill T; Marcellus D; Parker P; Johnson M; Kirk A; Porter D; Giralt S; Levine JE; Drobyski W; Barrett AJ; Horowitz M; Collins RH
Bone Marrow Transplant; 2000 Dec; 26(11):1179-84. PubMed ID: 11149728
[TBL] [Abstract][Full Text] [Related]
12. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
[TBL] [Abstract][Full Text] [Related]
13. Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma.
Reichardt VL; Okada CY; Stockerl-Goldstein KE; Bogen B; Levy R
Biol Blood Marrow Transplant; 1997 Aug; 3(3):157-63. PubMed ID: 9310193
[TBL] [Abstract][Full Text] [Related]
14. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
15. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect.
Bertz H; Burger JA; Kunzmann R; Mertelsmann R; Finke J
Leukemia; 1997 Feb; 11(2):281-3. PubMed ID: 9009093
[TBL] [Abstract][Full Text] [Related]
16. Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
Lee CK; Barlogie B; Zangari M; Fassas A; Anaissie E; Morris C; Van Rhee F; Cottler-Fox M; Thertulien R; Muwalla F; Mazher S; Badros A; Tricot G
Bone Marrow Transplant; 2002 Dec; 30(12):873-8. PubMed ID: 12476279
[TBL] [Abstract][Full Text] [Related]
17. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
[TBL] [Abstract][Full Text] [Related]
18. Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma.
Gertz MA; Lacy MQ; Inwards DJ; Gastineau DA; Tefferi A; Chen MG; Witzig TE; Greipp PR; Litzow MR
Bone Marrow Transplant; 2000 Jul; 26(1):45-50. PubMed ID: 10918404
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect.
Le Blanc R; Montminy-Métivier S; Bélanger R; Busque L; Fish D; Roy DC; Kassis J; Boileau J; Lavallée R; Bélanger D; Letendre F; Hébert J; Sauvageau G; Perreault C; Roy J
Bone Marrow Transplant; 2001 Nov; 28(9):841-8. PubMed ID: 11781644
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
Ahmad I; Islam T; Chanan-Khan A; Hahn T; Wentling D; Becker JL; McCarthy PL; Alam AR
Bone Marrow Transplant; 2002 Apr; 29(7):577-80. PubMed ID: 11979306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
